Insmed
INSM
#1051
Rank
C$32.57 B
Marketcap
C$150.28
Share price
-1.82%
Change (1 day)
7.48%
Change (1 year)

P/E ratio for Insmed (INSM)

P/E ratio as of July 2026 (TTM): -18.6

According to Insmed's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -18.5565. At the end of 2025 the company had a P/E ratio of -27.2.

P/E ratio history for Insmed from 2001 to 2026

PE ratio at the end of each year

Year P/E ratio Change
2025-27.2119.84%
2024-12.4
2022-5.12-27.22%
2021-7.04-36.36%
2020-11.140.79%
2019-7.86152.66%
2018-3.11-71.48%
2017-10.9134.03%
2016-4.66-47.9%
2015-8.946.92%
2014-8.36

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
Novartis
NVS
21.8-217.65%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Gilead Sciences
GILD
17.8-195.78%๐Ÿ‡บ๐Ÿ‡ธ USA
Vertex Pharmaceuticals
VRTX
27.9-250.39%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
-28.1 51.69%๐Ÿ‡บ๐Ÿ‡ธ USA
Aerie Pharmaceuticals
AERI
-20.3 9.58%๐Ÿ‡บ๐Ÿ‡ธ USA
Array Technologies
ARRY
-7.08-61.83%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.